251.45 0.00 (0.00%)
After hours: 5:14PM EST
|Bid||242.13 x 800|
|Ask||252.22 x 800|
|Day's Range||249.70 - 251.57|
|52 Week Range||199.85 - 253.91|
|Beta (3Y Monthly)||1.31|
|PE Ratio (TTM)||34.73|
|Earnings Date||Apr 23, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||0.68 (0.27%)|
|1y Target Est||269.75|
When Dai started his company in 1994, roadside surveillance cameras were rare in China. The 54-year-old former academic, who now drives a luxury sedan and rewards high-performing employees with BMWs, is the latest of at least four businessmen to amass billion-dollar-plus fortunes from surveillance companies that count China’s government as a major client or investor.
BEIJING (AP) — Thermo Fisher Scientific Inc. says it will no longer sell or service genetic sequencers in China's mostly Muslim region of Xinjiang following criticism that they were used for surveillance that enabled human rights abuses, The Wall Street Journal reported.
Thermo Fisher Scientific Inc. said Wednesday it will no longer be selling or servicing genetic sequencers in China’s Xinjiang region, following mounting criticism that its products were used for state surveillance of citizens there that enabled human rights abuses. It didn’t specify whether it would continue to sell these sequencers elsewhere in China. The devices were described in a December 2017 Wall Street Journal article that highlighted the ways Chinese police gather DNA samples from many citizens who aren’t criminal suspects.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Thermo Fisher Scientific Inc. (NYSE:TMO), a large-capRead More...
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Thermo Fisher Scientific Inc NYSE:TMOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for TMO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TMO. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding TMO totaled $16.52 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Industrials sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Thermo Fisher Scientific (TMO) bills itself as "the world leader in serving science." The life-sciences titan provides a variety of equipment, supplies, and services for both the research and practical sides of the healthcare market, Richard Moroney, editor of Dow Theory Forecasts.
CAMBRIDGE, Mass. and WALTHAM, Mass., Feb. 4, 2019 /PRNewswire/ -- Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, and Thermo Fisher Scientific Inc. (TMO), today announced a collaboration to build a dedicated Slipstream™ manufacturing facility for high-efficiency production of Torque's Deep-Primed T cell immunotherapies. Buildout of the Torque/Thermo Fisher manufacturing facility has begun, and the companies anticipate processing patient cells by the end of 2019. "Torque's cell manufacturing technology platform is critical to achieving our goal of developing and commercializing a new class of cellular immunotherapy for cancer patients with both early and advanced disease, particularly for the large population of solid tumor patients in need of new treatments," said Bart Henderson, CEO of Torque.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Thermo Fisher Scientific came in with "another monster" quarter on Wednesday — easily topping fourth-quarter expectations, one analyst noted. Thermo Fisher stock rose in midday action.
"Primarily we spend capital on (mergers and acquisitions). We’ve strengthened the balance sheet substantially, and the anatomical pathology sale will give us even more firepower to deploy over time," Thermo Fisher CEO Marc Casper said Wednesday.
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.88% and 4.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of $2.22. Earnings, adjusted for one-time gains and costs, were $3.25 per share. The results surpassed Wall Street ...
WALTHAM, Mass. , Jan. 30, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ...
Investing.com - Thermo Fisher Scientific (NYSE:TMO) reported fourth quarter earnings that beat analysts' expectations on Wednesday and revenue that topped forecasts.
Thermo Fisher Scientific (NYSE: TMO ) announces its next round of earnings this Wednesday, Jan. 30. Here's Benzinga's advanced look at Thermo Fisher Scientific's Q4 earnings report. Earnings and Revenue ...
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
(Reuters) - Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, will sell its anatomical pathology business for $1.14 billion in cash, the company said on Monday. The buyer ...